Literature DB >> 12699419

Discordant effects of interleukin-2 on viral and immune parameters in human immunodeficiency virus-1-infected monocyte-derived mature dendritic cells.

G M Bahr1, E C A Darcissac, Y Mouton.   

Abstract

Use of interleukin-2 (IL-2) in the immunotherapy of human immunodeficiency virus (HIV) has frequently resulted in the restoration of CD4 lymphocyte counts but not of virus-specific responses. We reasoned that the absence of reconstituted functional immune parameters could be related to the inability of IL-2 to correct HIV-induced dysfunctions in antigen-presenting cells. In this study, we used in vitro-differentiated monocyte-derived macrophages (MDMs) and mature dendritic cells (MDDCs), acutely infected with primary HIV-1 isolates, to analyse the effects of IL-2 on virus replication, co-receptor expression, and cytokine or chemokine release. Stimulation of MDMs with IL-2 had no measurable effect on HIV-1 replication, on cytokine secretion, or on CD4 and CXCR4 gene expression. Moreover, although a significant down-regulation of CCR5 mRNA expression could be repeatedly detected in MDMs, this IL-2-mediated effect was not of substantial magnitude to affect virus replication. On the other hand, IL-2 stimulation of MDDCs dramatically increased HIV-1 replication and this effect was highly evident on low-replicating, CXCR4-dependent isolates. Nevertheless, the HIV-enhancing activity of IL-2 in MDDCs was not accompanied by any measurable change in cytokine or chemokine release, in virus receptor and co-receptor mRNA accumulation, or in the surface expression of a battery of receptors implicated in virus entry, cell activation or costimulatory function. Taken together, these findings point to a role for IL-2 in inducing virus purging from dendritic cell reservoirs but indicate no relevant potential of the cytokine in restoring defective elements of innate immunity in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699419      PMCID: PMC1808691          DOI: 10.1046/j.1365-2249.2003.02143.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor.

Authors:  C Bovolenta; L Camorali; A L Lorini; G Vallanti; S Ghezzi; G Tambussi; A Lazzarin; G Poli
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

Authors:  E Connick; M M Lederman; B L Kotzin; J Spritzler; D R Kuritzkes; M St Clair; A D Sevin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; J D'Arc Roe; A Martinez; H Kessler; A Landay
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

3.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.

Authors:  J Blanco; C Cabrera; A Jou; L Ruiz; B Clotet; J A Esté
Journal:  AIDS       Date:  1999-04-01       Impact factor: 4.177

5.  Cofactors for human immunodeficiency virus entry into primary macrophages.

Authors:  R G Collman; Y Yi
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

6.  Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells.

Authors:  M J Truong; E C Darcissac; E Hermann; J Dewulf; A Capron; G M Bahr
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

Authors:  C R Rinaldo; J M Liebmann; X L Huang; Z Fan; Q Al-Shboul; D K McMahon; R D Day; S A Riddler; J W Mellors
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

8.  Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.

Authors:  A D Kelleher; M Roggensack; S Emery; A Carr; M A French; D A Cooper
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

9.  Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Authors:  D Cecilia; V N KewalRamani; J O'Leary; B Volsky; P Nyambi; S Burda; S Xu; D R Littman; S Zolla-Pazner
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.

Authors:  D Unutmaz; V N KewalRamani; S Marmon; D R Littman
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  2 in total

1.  Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS.

Authors:  Thangavel Samikkannu; Kurapati V K Rao; Nimisha Gandhi; Shailendra K Saxena; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2010-07       Impact factor: 2.643

2.  Displacement of SATB1-bound histone deacetylase 1 corepressor by the human immunodeficiency virus type 1 transactivator induces expression of interleukin-2 and its receptor in T cells.

Authors:  P Pavan Kumar; Prabhat Kumar Purbey; Dyavar S Ravi; Debashis Mitra; Sanjeev Galande
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.